MiRNA-425 has been already considered as therapeutic targets and biomarkers of cardiovascular disease because it binds to a polymorphic region of 3’UTR of its target atrial natriuretic peptide (ANP) mRNA. Here, NPPA is linked to cardiovascular disorder.